Miracell’s “Smart M-Cell 2” Targets the Middle East: Massive Stem Cell Extraction After Blood Concentration
Received Ministry of Health and Welfare “New Health Technology” certification
Performance demonstrated at Seoul National University Bundang Hospital
Praise received at Dubai Medical Equipment Exhibition
Miracell, a stem cell specialist, is aggressively targeting the Middle Eastern market following its European expansion.
Shin Hyun-soon, CEO of Miracell, recently met with Maeil Business Newspaper at the Miracell headquarters in Yeoksam-dong, Seoul.
“Miracell’s cutting-edge bio-stem cell extraction system is receiving enthusiastic responses in the Middle East, including the United Arab Emirates (UAE),” he said. “These afternoons are filled with Zoom meetings with Middle Eastern countries.”
Founded in 2009, Miracell’s core businesses include cell storage services, medical device and cosmetic manufacturing, and stem cell therapy. Stem cells are so small that they cannot be used immediately after extraction,
needing separation and concentration. Miracell developed its own stem cell extraction device, which received “New Health Technology” certification from the Ministry of Health and Welfare in February of last year.
The company’s “Smart M-cell 2” is a regenerative medical device that extracts bone marrow and blood, concentrates them through centrifugation, and then automatically extracts a large amount of isolated stem cells.
Approximately 2.9 billion cells can be extracted per session in less than an hour. Equipped with a special LED to enhance cell activity,
it is currently being used for therapeutic purposes at major hospitals in Korea.
CEO Shin stated, “Smart M-cell 2 has shown clinical trials at the Seoul Institute of Medical Science and Bundang Seoul National University Hospital
to outperform Harvard Medical School’s Immunology Research Institute’s “Smart Prep” in terms of cell viability and recovery rates.
Expectations are high.” He added, “Having received an enthusiastic response at the Dubai International Medical Device Exhibition earlier this year,
we will actively pursue our global market expansion, including in the Middle East.”
CEO Shin is also developing an app to popularize stem cell treatment. CEO Shin explained, “We will create a global platform that connects domestic and international patients with hospitals around the world,
making it easier for patients around the world to exchange treatment information.”
Reporter Yoo Joo-yeon